Prior aspirin use and outcomes in acute coronary syndromes
Jonathan D Rich1, Christopher P Cannon, Sabina A Murphy
1Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Insights
Prior aspirin use in acute coronary syndrome (ACS) patients is linked to more comorbidities and a higher risk of recurrent myocardial infarction (MI), but not mortality. Aspirin use may indicate a patient population at increased risk for adverse events post-ACS.
Area of Science:
- Cardiology
- Clinical Research
- Epidemiology
Background:
- Controversy exists regarding whether prior aspirin use independently predicts worse outcomes in patients experiencing acute coronary syndrome (ACS).
- Understanding the implications of pre-ACS aspirin use is crucial for risk stratification and management.
- This study addresses the debate on aspirin's impact on ACS patient outcomes.
Purpose of the Study:
- To determine if patients taking aspirin before an acute coronary syndrome (ACS) face a higher risk of recurrent events or mortality.
- To analyze the association between pre-ACS aspirin use and patient characteristics, ACS severity, and clinical outcomes.
- To clarify the role of prior aspirin use as a predictor of adverse events after ACS.
Main Methods:
- A large cohort of 66,443 ACS patients was analyzed using a merged database from previous Thrombolysis in Myocardial Infarction trials.
- Differences in ACS type, total mortality, and a composite endpoint (death, MI, recurrent ischemia, stroke) were compared between prior aspirin and non-aspirin users.
- Multivariate analysis was employed to control for baseline patient characteristics and confounding factors.
Main Results:
- Prior aspirin users (n=17,839) were older with more coronary risk factors and disease evidence compared to non-users (n=48,604).
- Aspirin use was associated with less severe ACS presentations (e.g., unstable angina > NSTEMI > STEMI).
- No significant difference in total mortality was observed at 30 days or long-term follow-up; however, prior aspirin use was linked to a modest increase in recurrent MI and the composite endpoint.
Conclusions:
- Prior aspirin use in ACS patients correlates with increased comorbidities and coronary disease burden.
- While not associated with increased mortality, prior aspirin use predicts a higher risk of recurrent myocardial infarction.
- Pre-ACS aspirin use should be recognized as a marker identifying patients at high risk for recurrent adverse events.
Objectives:
The purpose of this study was to determine whether patients taking aspirin before an acute coronary syndrome (ACS) are at higher risk of recurrent events or mortality.
Background:
Controversy exists whether prior aspirin use is an independent predictor of worse outcomes in patients who experience an ACS.
Methods:
We evaluated 66,443 ACS patients from a merged database of previous Thrombolysis in Myocardial Infarction trials. We evaluated the differences in ACS type, total mortality, and the composite end point of death, myocardial infarction (MI), recurrent ischemia, or stroke between prior aspirin and nonprior aspirin users. We used multivariate analysis to control for differences in baseline characteristics.
Results:
Prior aspirin users (n = 17,839) were older (63 years vs. 59 years) and had more coronary risk factors and evidence of coronary artery disease (MI, angina, prior intervention) than nonprior aspirin users (n = 48,604) (all p < 0.0001). Prior aspirin use was associated with less severe types of ACS at presentation (e.g., unstable angina > non-ST-segment elevation MI > ST-segment elevation MI) than their nonaspirin user counterparts (p < 0.0001). After multivariate analysis, there was no difference in total mortality between prior aspirin users and nonaspirin users at day 30 (odds ratio [OR]: 1.01; 95% confidence interval [CI]: 0.90 to 1.13) or by the last follow-up visit (mean 328 days) (hazard ratio: 1.03; 95% CI: 0.95 to 1.11). Prior aspirin use was modestly associated with recurrent MI (OR: 1.26; 95% CI: 1.12 to 1.43) and the composite end point (OR: 1.16; 95% CI: 1.08 to 1.24).
Conclusions:
Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but not mortality. As such, it should best be considered a marker of a patient population at high risk for recurrent adverse events after ACS.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome I: Introduction
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...